Companies

Synairgen

Overview

Synairgen is a developer of respiratory drugs. The main project uses inhaled interferon beta for the treatment of viral infection in asthma and chronic obstructive pulmonary disease (COPD). Synairgen floated in October 2004, when it raised £10m - £9m net of expenses - at 130p a share. That valued the company at £28.2m. Synairgen raised £6.35m at 17p a share in June 2009. (www.synairgen.com)

Sector: Health

News blog

• Synairgen Posted: 03/10/2010
• Synairgen Posted: 14/02/2010
• Synairgen Posted: 09/11/2009
• Synairgen Posted: 06/09/2009

Browse by sector

All companies

• Aim advisers
• Aim Awards
• Aim investor relations
• Cleantech
• Construction
• Consumer
• Electricals
• Financial
• Food
• Health
• Industrial
• Leisure
• Media
• Mobile
• Property
• QUOTED MICRO
• Resources
• Retail
• Security
• Services
• Technology
• Telecoms
• Training
• Transport

• 2.4mNumber of messages posted on SocialGo networks
  
• $38mCost savings generated by ideas from WalMart staff over a two month period